3M (MMM) Q2 2025 earnings summary

Executive summary

• Q2 2025 net sales were $6.34B, up 1.4% year-over-year, with organic growth of 1.5% and adjusted sales at $6.2B; all business groups posted positive organic growth for the third consecutive quarter.

• Adjusted EPS for Q2 was $2.16, up 12% year-over-year, while GAAP EPS was $1.34, down 38% due to litigation and special items; adjusted operating margin improved to 24.5%, up 2.9 percentage points.

• Free cash flow for Q2 was $1.3B with conversion above 100%, despite negative operating cash flow from $2.2B in after-tax litigation payments.

• 126 new products launched in H1, with five-year new product sales up 9%; commercial excellence initiatives and OTIF service metrics reached multi-year highs.

• Completed the spin-off of Solventum in April 2024, now reported as discontinued operations.

Financial highlights

• H1 2025 sales were $12.3B, up 0.2% year-over-year; adjusted operating margin for Q2 was 24.5%, up 290 bps, and H1 margin was 24.0%, up 250 bps.

• H1 2025 EPS was $4.04, up 11% year-over-year; Q2 net income from continuing operations was $723M, down from $1.2B a year ago.

• Returned $3B to shareholders in H1 via $2.2B in share repurchases and $0.8B in dividends; $1.3B returned in Q2.

• Cash and cash equivalents at quarter-end were $3.7B, down from $5.6B at year-end 2024.

• Price realization contributed 70 bps for the year, offsetting material cost inflation and tariff headwinds.

Outlook and guidance

• Full-year 2025 adjusted EPS guidance raised to $7.75–$8.00, inclusive of tariff impacts; organic revenue growth guidance updated to ~2%.

• Adjusted total sales growth expected at ~2.5%; margin expansion of 150–200 bps and free cash flow conversion above 100%.

• Capital spending for 2025 expected to be ~$1.0B, focused on growth, productivity, and sustainability.

• Second-half EPS growth expected at $0.18 at midpoint, with volume growth and productivity offset by tariff and higher interest expense.

• Company intends to divest its 19.9% Solventum stake within five years of the April 2024 spin-off.